赛登法律宣布，美国股东成立了一个小组，以通过对总部位于中国Bio-pharm Asia, Inc.（股票代码：BFAR）的潜在收受人提起诉讼，来追回投资者资金。
BioPharm Asia, Inc., (ticker:”BFAR”), is a Nevada corporation involved in the sale of medical products to drug stores, hospitals, neighborhood clinics, and other medicine retail outlets in the People’s Republic of China. BFAR was de-listed from the NASDAQ in June 2013 after it stopped reporting to the Securities & Exchange Commission (“SEC”).
一些股东已与纽约的罗伯特·W·赛登恩律师联系，以代表一群股东，维护美国股东的权益，以制止那些损害投资者利益的行为，包括未能向美国证券交易委员会报告，从而无法让投资者获得潜在的资本回报。.
